Updated results from a phase II trial of Reolysin and paclitaxel in ovarian cancer patients showed that an intent-to-treat analysis of tumor response, as assessed by CA-125 antigen levels, demonstrated statistically significantly higher full response rates and stable disease or better rates in the test arm compared to paclitaxel alone.
Jed Manocherian wants your attention—but not for himself.
